Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.

Abstract excerpt

For patients with locally advanced or metastatic melanoma who have BRAF V600 activating mutations, combination therapy with BRAF and MEK inhibitors is now the standard of care. The combination of encorafenib, a highly selective adenosine triphosphate-competitive BRAF inhibitor, plus binimetinib, a potent, selective, allosteric, non-adenosine triphosphate-competitive MEK1/2 inhibitor, was approved by the US Food...

Topics

Join the communities discussing this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Melanoma
• Mitogen-Activated Protein Kinase Kinases
• Mutation
• Protein Kinase Inhibitors